Motif Bio (MTFB) PT Lowered to GBX 106 at Peel Hunt

Motif Bio (LON:MTFB) had its target price reduced by Peel Hunt from GBX 107 ($1.48) to GBX 106 ($1.46) in a report released on Tuesday morning. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on the stock. FinnCap reaffirmed a buy rating and issued a GBX 100 ($1.38) price objective on shares of Motif Bio in a research report on Wednesday, November 22nd. Northland Securities reaffirmed a buy rating on shares of Motif Bio in a research report on Friday, December 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of GBX 101.50 ($1.40).

How to Become a New Pot Stock Millionaire

Motif Bio (MTFB) opened at GBX 31 ($0.43) on Tuesday. Motif Bio has a 12-month low of GBX 23.50 ($0.32) and a 12-month high of GBX 51.75 ($0.71). The stock has a market cap of $93.75 and a P/E ratio of -119.23.

ILLEGAL ACTIVITY NOTICE: “Motif Bio (MTFB) PT Lowered to GBX 106 at Peel Hunt” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3294655/motif-bio-mtfb-pt-lowered-to-gbx-106-at-peel-hunt.html.

About Motif Bio

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Analyst Recommendations for Motif Bio (LON:MTFB)

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

IHI  & Intevac  Financial Comparison
IHI & Intevac Financial Comparison
Contrasting Jamba Juice  and Dunkin’ Brands
Contrasting Jamba Juice and Dunkin’ Brands
Hudson’s Bay  Receives Consensus Rating of “Hold” from Analysts
Hudson’s Bay Receives Consensus Rating of “Hold” from Analysts
TUI Group  Receives Consensus Recommendation of “Buy” from Analysts
TUI Group Receives Consensus Recommendation of “Buy” from Analysts
Premier Oil  Given Average Rating of “Hold” by Brokerages
Premier Oil Given Average Rating of “Hold” by Brokerages
Axovant Sciences  Getting Somewhat Positive Press Coverage, Study Finds
Axovant Sciences Getting Somewhat Positive Press Coverage, Study Finds


© 2006-2018 Ticker Report. Google+.